COMPE protocol

chemotherapy protocol consisting of cisplatin, vincristine, methotrexate, etoposide, and peplomycin for the treatment of testicular choriocarcinoma

Networked: 0 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - COMPE protocol
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - COMPE protocol
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - COMPE protocol
Inorganic Chemicals: 9
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        Podophyllotoxin: 562
        Etoposide: 10706
        COMPE protocol
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        COMPE protocol
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - Etoposide: 10706
      - COMPE protocol
- Glycoconjugates: 1353
  - Glycopeptides: 1928
    - Bleomycin: 9833
      - Peplomycin: 343
        COMPE protocol
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vincristine: 9251
        COMPE protocol
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Glycopeptides: 1928
    - Bleomycin: 9833
      - Peplomycin: 343
        COMPE protocol